Chardan Capital Reiterates “Buy” Rating for Ocugen (NASDAQ:OCGN)
Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research note issued on Monday,Benzinga reports. They currently have a $6.00 price objective on the stock. Other research analysts also recently issued research reports about the company. Maxim Group assumed coverage on Ocugen in a […]
More Stories
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Significant Increase in Short Interest
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN – Get Free Report) was the target of a large growth in short interest in October....
C&F Financial Co. (NASDAQ:CFFI) Sees Significant Decline in Short Interest
C&F Financial Co. (NASDAQ:CFFI – Get Free Report) was the recipient of a large decline in short interest during the...
Coinbase Global, Inc. (NASDAQ:COIN) Short Interest Update
Coinbase Global, Inc. (NASDAQ:COIN) was the recipient of a large drop in short interest during the month of October. As...
Invesco S&P 500 Equal Weight Health Care ETF (NYSEARCA:RYH) Sets New 12-Month Low – What’s Next?
Shares of Invesco S&P 500 Equal Weight Health Care ETF (NYSEARCA:RYH – Get Free Report) reached a new 52-week low...
Cullen/Frost Bankers, Inc. (NYSE:CFR) Short Interest Down 8.4% in October
Cullen/Frost Bankers, Inc. (NYSE:CFR – Get Free Report) was the recipient of a large drop in short interest in October....
Golub Capital BDC, Inc. (NASDAQ:GBDC) Short Interest Down 8.0% in October
Golub Capital BDC, Inc. (NASDAQ:GBDC – Get Free Report) saw a large drop in short interest in the month of...